AbbVie Reports long-term follow-up Data for Pertuzumab in Cervical cancer

AbbVie today announced long-term follow-up results for pertuzumab in patients with cervical cancer. The study demonstrated that pertuzumab improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of cervical cancer and support the continued development of pertuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.